# Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

> **NCT04830449** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 122 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1904-2
- **DRUG:** RLD2001-2

## Key facts

- **NCT ID:** NCT04830449
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-29
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830449, "Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04830449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*